[Chinese guidelines on the diagnosis and treatment of adult essential thrombocythemia (2026)].

Authors

Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association

Published in

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. Volume 47. Issue 5. Pages 409-423. May 14, 2026.

Abstract

Essential thrombocythemia (ET) is a classic Philadelphia chromosome-negative myeloproliferative neoplasm characterized by excessive proliferation of bone marrow megakaryocytes and sustained elevation of peripheral blood platelet counts. The primary clinical risks include thrombotic and bleeding events, with a minority of patients experiencing the risk of progression to myelofibrosis or transformation to acute leukemia. In recent years, the demand for standardized diagnosis and treatment of ET has become increasingly prominent with advances in molecular testing, bone marrow pathology diagnosis, novel drug development, and clinical management. To provide actionable clinical practice guidance for hematologists in China, the Thrombosis and Hemostasis Group of the Chinese Society of Hematology, Chinese Medical Association, convened domestic experts to formulate this guideline, based on both international and domestic evidence-based medical evidence combined with expert consensus.

PMID:
42409729
Bibliographic data and abstract were imported from PubMed on 07 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.